Blueprint Medicines Corp. (NASDAQ:BPMC) rose 4.3% on Friday . The stock traded as high as $25.26 and last traded at $25.11, with a volume of 68,704 shares traded. The stock had previously closed at $24.08.

BPMC has been the topic of several analyst reports. Cowen and Company reaffirmed a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. Canaccord Genuity began coverage on shares of Blueprint Medicines Corp. in a report on Friday, August 5th. They set a “buy” rating and a $26.00 price objective on the stock. Raymond James Financial Inc. began coverage on shares of Blueprint Medicines Corp. in a report on Friday, May 27th. They set an “outperform” rating and a $23.00 price objective on the stock. Zacks Investment Research lowered shares of Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Finally, TheStreet raised shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $29.43.

The firm’s market cap is $671.42 million. The stock’s 50-day moving average price is $21.18 and its 200-day moving average price is $18.43.

Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its earnings results on Tuesday, August 9th. The company reported ($0.70) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.03. During the same period in the prior year, the business posted ($0.81) EPS. The firm had revenue of $7.07 million for the quarter, compared to analyst estimates of $4.41 million. The firm’s quarterly revenue was up 163.0% compared to the same quarter last year. Analysts anticipate that Blueprint Medicines Corp. will post ($2.98) earnings per share for the current year.

In other news, CEO Jeffrey W. Albers sold 17,000 shares of Blueprint Medicines Corp. stock in a transaction on Monday, August 8th. The stock was sold at an average price of $22.86, for a total transaction of $388,620.00. Following the completion of the sale, the chief executive officer now owns 76,494 shares of the company’s stock, valued at $1,748,652.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC boosted its position in Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned 2.73% of Blueprint Medicines Corp. worth $19,500,000 as of its most recent SEC filing.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.